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What you have inherited from your fathers, acquire it
in order to possess it
[Was du ererbt von deinen Vätern hast, erwirb es, um
es zu besitzen]
Goethe
Faust
Juvenile idiopathic arthritis (JIA), the most frequent
chronic inXammatory disease in cildren and adolescents, is
deWned by the most accurate description of seven exclusive
subtypes [1]. In contrast, the latest classiWcation criteria for
rheumatoid arthritis (RA), a joint project by the European
League against Rheumatism (EULAR) and the American
College of Rheumatology (ACR), describe the disorder by
criteria that compel the attending rheumatologist to pre-
scribe a disease-modifying antirheumatic drug, mostly
methotrexate [2]. Investigators mainly from North America
and endorsed by the ACR have chosen a similar path by
deWning treatment groups for JIA and giving recommenda-
tions for the treatment of JIA [3]. Beukelman and coinvesti-
gators  Wrst assembled the relevant literature excluding
review articles between 1966 and 2009 and found 221 arti-
cles that were reviewed and abstracted by a group of
experts. Since diVerential treatment between the diVerent
categories of JIA is not established, the authors developed
treatment groups that are in part similar to older categories
of pediatric rheumatic disorders including oligoarthritis,
polyarthritis, sacroiliac arthritis, systemic arthritis with sys-
temic features and systemic arthritis with arthritis. For each
category, they deWned features of poor prognosis and three
levels of disease activity. Finally, the authors created 1,539
clinical scenarios with a given treatment group and history
of treatment and description of disease activity and progno-
sis. All these scenarios were evaluated individually by each
member of a task force of experts, practitioners and a par-
ent and assessed for the appropriateness of initiating a cer-
tain treatment option. The expert group then translated the
results into text and Wnally determined the level of evidence
of each recommendation. The authors added algorithms for
four of the Wve treatment groups. Beukelman et al. have
undertaken a gigantic project and achieved an unparalleled
step ahead in the development of pediatric rheumatology.
Already in the introduction, the authors admit that they
did not consider indications for systemic glucocorticoids
for the treatment of synovitis since they could not Wnd any
published evidence [3]. This is a remarkable statement
since generations of pediatric rheumatologists have relied
on the administration of systemic glucocorticoids and were
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and are experts in using the beneWcial antirheumatic prop-
erties while avoiding the adverse eVects.
In fact, there are several reasons to question the appro-
priateness of excluding systemic glucocorticoids from the
treatment of arthritis in children with JIA.
• It is textbook knowledge that synovitis is amenable to
treatment with systemic glucocorticoids including a long
record of eYcacy and adverse eVects. The vast knowl-
edge of adverse eVects of glucocorticoids and the ”intel-
ligent” use of glucocorticoids for the beneWt of the
patient while avoiding the unwanted eVects are proof of
the extensive knowledge of eYcacy. Intelligent use of
glucocorticoids includes topical administration such as
intra-articular glucocorticoids (which are being accepted
by Beukelman et al.), low-dose glucocorticoids, which
implies the avoidance of cushingoid side eVects, and glu-
cocorticoid pulse therapy which may be repeated after a
few weeks without the occurrence of long-term adverse
eVects [4]. So, there is ample knowledge on the treatment
of arthritis with systemic steroids, but this predates the
introduction of controlled trials.
• There is good evidence for the appropriateness of using
several biological DMARDs because these new sub-
stances were required to demonstrate eVectiveness in
controlled trials prior to obtaining an FDA/EMA license
for children. Such randomized placebo-controlled trials
are costly, and there is no Wnancial incentive to test how
the oldest antirheumatic drug on the market, glucocorti-
coids, could be most reasonably used. Consequently, the
authors’ path favors new costly therapies and neglects
old inexpensive treatments such as glucocorticoids that
have been available for decades.
• Glucocorticoids can be administered in various ways,
i.e., oral, i.v., local, the dosage per kg body weight and
the distribution of the doses over the day, the duration of
treatment (days, weeks or months) and the repetition of
treatment as in pulse therapies vary widely and many
regimens have been described as being eVective. These
extreme variations render handling of this drug in the
authors’ project very diYcult if not impossible. How-
ever, if a probably very valuable drug cannot be assessed
by an analytical method, the consequence should be to
admit this methodological problem rather than the exclu-
sion of the drug.
• The authors do not discuss the concept of glucocorticoids
as a bridging agent. Systemic glucocorticoids render
rapid relief to patients with polyarthritis during the
period from initiation of slowly acting drugs including
methotrexate till the onset of their eYcacy.
• The actual algorithms for the treatment of polyarticular
JIA include the administration of systemic glucocorti-
coids. In fact, all recent controlled studies allowed for the
administration of low-dose glucocorticoids [5]. If the
authors believe glucocorticoids are not necessary, they
should have recommended testing their new approach
against standard treatment, i.e.,
methotrexate + glucocorticoids versus methotrexate
alone or versus methotrexate + early introduction of
TNF--blocker rather than excluding glucocorticoids.
• The concept proposed by the authors argues for the early
introduction of biological DMARDs including TNF--
blocker [3]. The therapeutic eYcacy and the safety
record of these drugs are impressive. However, the unre-
solved debate on the rare, but possible induction of
malignant lymphoma due to administration of TNF--
blockers should remind us of the necessity of continuing
vigilance. The wide variation between studies excluding
or showing an association of the treatment with TNF--
blockers and the detection of malignant lymphoma might
be due to the administration of systemic glucocorticoids
in several treatment protocols. Glucocorticoids have a
long record of antilymphoproliferative activity and might
have curbed development of lymphomas at a very early
stage. We should remember that the Wrst trials in which
children obtained TNF--blockers are just a decade ago
and there are no patients with JIA in their forties who
received biological DMARDs in their childhood [6]. So,
in the absence of long-term safety data, biological
DMARDs should be started when conventional treat-
ment with methotrexate and glucocorticoids has failed.
• The strongest argument for the early introduction of
TNF--blockers rests on the assumption that early and
aggressive treatment of RA may prevent deWnitive dam-
age due to suppression of inXammation and pannus for-
mation and even might hinder the establishment of the
false immune reaction leading to chronic inXammatory
joint disease. However, in contrast to RA, the pathogene-
sis of JIA does not progress rapidly to joint destruction
with the exception of a few cases of rheumatoid factor
positive polyarticular JIA that resembles RA starting
already in adolescence. There is no lasting damage in
JIA and no loss of a window of opportunity during the
period of the slowly starting eYcacy of methotrexate
especially in the presence of concomitant treatment with
systemic glucocorticoids.
We believe it is wrong to withhold systemic glucocorticoids
from children with polyarticular JIA. It is correct that the
eYcacy of the drug should be tested in controlled trials. The
lack of the appropriate evidence is the pediatric rheumatol-
ogy community’s fault and this negligence should not lead to
our patients’ disadvantage. We have to acquire the drug in
our modern way by controlled trials. Till these results will be
available, we should keep the drug and continue using it
based on the therapeutic experience of the last decades.Rheumatol Int (2011) 31:1259–1262 1261
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The authors suggest updating their recommendations
which is laudable [3]. However, they should not only focus
on areas of newly published evidence, but include available
older knowledge on eVective treatment of JIA and trans-
form it into new evidence by controlled studies. Moreover,
the authors might consider broadening the basis of their
recommendations by including the Pediatric Rheumatology
European Society. Recent recommendations concerning
RA were jointly published by ACR and EULAR.
Further criticisms include:
• Tocilizumab is not mentioned since the authors claim the
drug is not widely commercially available. It is licensed
for JIA in Japan, for systemic JIA in the US and for RA
in Europe and has just been licensed for systemic JIA in
Europe.
• Hydroxychloroquine is labeled inappropriate for active
synovitis [3]. However, the results of trials are inconclu-
sive and the largest study included patients with severe
arthritis and an unexplained improvement in the placebo
group [7]. The drug is known to act very slowly and if
there are other means including intra-articular steroids to
control acute arthritis, it may well prevent Xare with a
very good safety record.
• Rituximab is recommended as a possible alternative
when TNF--blocker and abatacept have failed. This is
based solely on references concerning RA. There is no
pediatric evidence beyond case reports. The drug is
known to aVect permanently the growing B-cell-com-
partment in children and there are no data on long-term
safety. Rituximab should be reserved for very rare cases
or given in controlled trials in JIA only.
• Methotrexate is recommended at 15 mg/m2 administered
by parenteral route. The drug usually is given at 10–
12 mg/m2, and there is no convincing evidence in chil-
dren that the parenteral route is superior to the oral route
which might be more appropriate for children. Most of
the recent controlled trials for the assessment of new bio-
logical DMARDs included as an inclusion criterion fail-
ure or toxicity of oral methotrexate at the lower dosage.
A PRINTO study demonstrated the eYcacy of 15 mg/m2
via the parenteral route after 8–12.5 mg/m2 orally had
failed [8]. However, the study had no control group and
continuation of the oral treatment might have been
equally eVective. Thus, when oral methotrexate fails to
control arthritis, a TNF--blocker may be considered
without having administered parenteral methotrexate.
• Abatacept is a special, although instructive, case: there is
a single-controlled trial in polyarticular JIA which
showed eYcacy and which was followed by FDA and
EMA approval [9]. The authors recommend the drug for
polyarticular JIA which did not improve on TNF--
blockers. However, there are no other data conWrming
the initial publication, and there are no data on long-term
safety. It is not enough to show a drug’s eYcacy in one
controlled trial. The drug has to show consistent eYcacy
over years and a good safety record which can be deter-
mined by registries as has been shown for etanercept
[10–13]. Such registries are missing for abatacept, toc-
ilizumab and adalimumab. Manufacturers should be
forced to continue surveillance of drug safety and
eYcacy after license under the threat of revoking license
if there is lack of compliance.
• The authors use scenarios based on key clinical decision
parameters (disease phenotype, prognostic features, dis-
ease activity and current therapy). They state that the
deWnitions and values of all these key parameters were
“as evidence-based as possible” [3]. However, the pro-
cess of achieving evidence obviously was based upon
expert opinion on “their personal clinical experience”
gathered via electronic mail. This discrepancy between
the strict adherence to evidence from controlled trials on
therapeutic agents on the one hand and the method of
deWning key parameters of patient stratiWcation on the
other hand is remarkable.
• As the authors point out, their recommendations require
clear deWnitions of disease activity including biomarkers
to make rational therapeutic choices. While certainly
normal levels of C-reactive protein and erythrocyte sedi-
mentation rate are consistent with the deWnition of low
disease activity, there is evidence that these measures are
not sensitive enough to exclude local inXammatory activ-
ity related to joint destruction. The need for more sophis-
ticated molecular markers indicating disease activity but
also prognosis is evident, and Wrst encouraging examples
have recently been published in JIA [14].
Our remarks are meant to encourage discussion and not to
belittle the tremendous progress for the treatment of JIA
which has been achieved by creating these recommenda-
tions. The authors have altered the approach to the patient
with JIA by creating the JIA treatment groups, by establish-
ing features of poor prognosis and by formulating diVerent
levels of disease activity. Use of these features all over the
world will show if these new tools will stand up against the
necessities of daily care and how they might be modiWed.
However, treating children with JIA will not be the same as
before the publication of these recommendations.
Summary
Investigators mainly from North America have established
a new classiWcation of juvenile idiopathic arthritis (JIA) by
creating treatment groups, levels of disease activity and
prognostic features [3]. After scanning the available litera-1262 Rheumatol Int (2011) 31:1259–1262
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ture for controlled trials the authors recommend treatment
options. Due to the lack of published evidence these
authors could not Wnd an indication for the use of systemic
steroids in chronic synovitis. Since this drug may be very
useful for patients with JIA and its introduction predates
evidence-based medicine, it should not be removed from
treatment algorithms, but should be tested in controlled tri-
als. Further topics of discussion relate to treatment with
tocilizumab, rituximab, methotrexate, hydroxychloro-
quine, abatacept and to varying levels of evidence in treat-
ment recommendations. Beukelman et al. will have a
lasting impact on the treatment of JIA. European Societies
for Pediatric Rheumatology should participate in future
developments.
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